Cambridge, UK – 20 February 2012 - Lab21 Limited, the global specialist in personalized medicine and clinical diagnostics, today announces the appointment of Fraser Logue as Group Director of Quality, Regulatory Affairs & Operations Excellence based in the UK.
Dr Logue served two decades in divisions of Abbott Laboratories, most recently as Division Vice President World Wide Manufacturing for Abbott Diabetes Care, moving from Division Vice President European Operations. He previously served as Operations Director for Abbott Diagnostics Division Ireland, Director of Quality & Regulatory and Marketing Manager for Abbott Diagnostics Division in Germany.
Graham Mullis, CEO of Lab21, said: “I am delighted to have someone of Fraser’s experience join Lab21, especially at a time when we expect to see significant organic growth during the next few years. His senior level international management experience and operations capabilities will ensure Lab21 will meet the demands of increasing sales, entering new markets including the US and the launch of new products.”
Dr Logue said: “Lab21 has achieved remarkable progress within the past 4 years, growing five times in size. I am looking forward to working with and contributing to the future success of Lab21.”
For further information:
Graham Mullis, CEO
t: +44 (0)1223 395450
For media and investor enquiries:
Nicole Yost/Dimithri Wignarajah
t: +44 (0)20 7457 2020
Lab21 is a global leader in personalized healthcare. It provides diagnostic products and services and supports blood bank screening, medical diagnostics and drug discovery. Lab21 customers include international healthcare providers, pharmaceutical and diagnostic companies. The Products division of Lab21 manufactures immunodiagnostic kits and reagents that are distributed internationally and is focused on infectious diseases for the blood-banking and clinical markets. Our clinical services operations have a growing test portfolio providing companion diagnostics and high technology molecular assays. Lab21's corporate offices are based in Cambridge, UK and Greenville, South Carolina, with a GMP manufacturing site in Cambridge and other manufacturing facilities in Newmarket, Camberley, Manchester and Bridport. Website: www.lab21.com